Clinical considerations in Parkinson's disease cell therapy

Jun Xue; Yifan Wu; Yuting Bao; Minglai Zhao; Fangzhou Li; Jing Sun; Yimin Sun; Jian Wang; Liang Chen; Ying Mao; Jeffrey S Schweitzer; Bin Song

doi:10.1016/j.arr.2022.101792

Clinical considerations in Parkinson's disease cell therapy

Ageing Res Rev. 2023 Jan:83:101792. doi: 10.1016/j.arr.2022.101792. Epub 2022 Nov 17.

Authors

Jun Xue¹, Yifan Wu¹, Yuting Bao¹, Minglai Zhao¹, Fangzhou Li¹, Jing Sun², Yimin Sun³, Jian Wang³, Liang Chen¹, Ying Mao⁴, Jeffrey S Schweitzer⁵, Bin Song⁶

Affiliations

¹ Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai 200040, China; National Center for Neurological Disorders, Shanghai Key Laboratory of Brain Function and Restoration and Neural Regeneration, Neurosurgical Institute of Fudan University, Shanghai Clinical Medical Center of Neurosurgery, Shanghai 200040, China.
² Institute for Translational Brain Research, State Key Laboratory of Medical Neurobiology, MOE Frontiers Center for Brain Science, Fudan University, Shanghai 200032, China.
³ Institute of Neurology, National Clinical Research Center for Aging and Medicine, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai 200032, China.
⁴ Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai 200040, China; National Center for Neurological Disorders, Shanghai Key Laboratory of Brain Function and Restoration and Neural Regeneration, Neurosurgical Institute of Fudan University, Shanghai Clinical Medical Center of Neurosurgery, Shanghai 200040, China. Electronic address: maoying@fudan.edu.cn.
⁵ Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA. Electronic address: jschweitzer1@mgh.harvard.edu.
⁶ Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai 200040, China; Institute for Translational Brain Research, State Key Laboratory of Medical Neurobiology, MOE Frontiers Center for Brain Science, Fudan University, Shanghai 200032, China. Electronic address: binsong@fudan.edu.cn.

PMID: 36402405
DOI: 10.1016/j.arr.2022.101792

Abstract

Cell replacement therapy is an area of increasing interest for treating Parkinson's disease (PD). However, to become a clinically practical option for PD patients, it must first overcome significant barriers, including establishment of safe and standardized surgical procedures, determination of appropriate perioperative medication regimens, demonstration of long-term graft survival and incorporation, and standardized, clinically meaningful follow-up measures. In this review, we will describe the current status of cell therapy for PD with special attention to these critical requirements, to define guideposts on the road to bring the benefit of this therapy to the Parkinson's clinic.

Keywords: Cell therapy; Clinical trial; Dopamine cells; Parkinson’s disease; Transplantation.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Cell- and Tissue-Based Therapy
Humans
Parkinson Disease* / therapy